Logotype for Kymera Therapeutics Inc

Kymera Therapeutics (KYMR) Q3 2026 earnings summary

Event summary combining transcript, slides, and related documents.

Logotype for Kymera Therapeutics Inc

Q3 2026 earnings summary

2 Nov, 2026

Executive summary

  • KT-579 Phase 1 showed ≥90% median IRF5 degradation across multiple-dose cohorts, broad biomarker modulation across immune pathways and placebo-comparable safety.

  • KT-621 is in Phase 2b trials for atopic dermatitis and asthma; KT-579’s LUMORA lupus Phase 1b study is planned for early 2027.

Financial highlights

  • Q3 collaboration revenue was $0, versus $2.764M in Q3 2025; no additional collaboration revenue is expected in 2026.

  • Q3 R&D expense was $128.509M versus $74.094M; G&A was $18.7M versus $17.3M.

  • Q3 net loss was $131.999M versus $82.175M; diluted loss per share was $1.32 versus $0.94.

  • Nine-month collaboration revenue was $99.365M versus $36.341M; net loss was $262.444M versus $224.370M.

  • Q3 adjusted cash R&D was $117.6M, up 8% QoQ; adjusted cash G&A was $10.8M, down 14% QoQ.

Outlook and guidance

  • KT-621 BROADEN2 atopic dermatitis results are expected by year-end 2026; the first AD Phase 3 trial is targeted for mid-2027, subject to supportive results and FDA alignment.

  • KT-621 BREADTH asthma Phase 2b results are expected in late 2027; KT-579 LUMORA lupus trial start is planned by early 2027.

  • KT-200 IND filing is targeted for 2027; Gilead is conducting IND-enabling studies.

  • Cash and securities of $1,645.883M at September 30, 2026 are expected to fund operations into 2029; R&D and G&A are expected to rise as development advances.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
All investor relations material. One API.
Learn more

Latest events from Kymera Therapeutics